Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’

Gabriella Fabbrocini and Fabrizio Martora Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy E-mail: angeloruggiero1993@libero.it Conflict of interest: the authors declare that they have no conflicts of interest. Funding: none. Ethics statement. Ethics approval and informed consent not applicable. Data availability: not applicable. Accepted for publication 30 May 2022

[1]  J. Thyssen,et al.  Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? , 2022, Clinical and experimental dermatology.

[2]  G. Fabbrocini,et al.  Hidradenitis suppurativa flares following COVID-19 vaccination: A case series , 2022, JAAD Case Reports.

[3]  G. Fabbrocini,et al.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review , 2022, Biomedicines.

[4]  G. Fabbrocini,et al.  A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa? , 2022, Skin Appendage Disorders.

[5]  G. Fabbrocini,et al.  Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  G. Fabbrocini,et al.  Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa , 2020, Dermatologic therapy.

[7]  C. Zouboulis,et al.  Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa , 2019, Dermatology.

[8]  C. Harview,et al.  Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study , 2019, The Journal of dermatological treatment.

[9]  G. Fabbrocini,et al.  Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side‐effects, improving patients’ compliance , 2019, The British journal of dermatology.

[10]  G. Fabbrocini,et al.  Unconventional therapies for hidradenitis suppurativa , 2018, Expert review of clinical pharmacology.

[11]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.